X-Therma, a San Francisco, CA-based biotechnology company developing a platform for regenerative medicine and organ preservation, raised $22.4M in Series B funding.
The round was led by Starling Locke Capital and Lorea, along with participation from new and existing investors.
The company intends to use the funds to scale global commercial operations and facilitates progression into the clinical stage with food and drug administration (FDA) breakthrough device status, aimed at increasing organ availability for transplantation by overcoming time-sensitive limitations.
Led by CEO Xiaoxi Wei, X-Therma is developing cold chain technology via a convergent biopreservation platform, to advance regenerative medicine and make available safe and on-demand organs, engineered tissues, cell and gene therapies, vaccines, and beyond to patients in need.
The investment will advance multiple key products in X-Therma’s development pipeline:
- XT-Thrive®and XT-NoVoTM for regenerative medicine and cell therapy, and
- XT-ViVo® & TimeSeal® for organ preservation for transplantation, which receivedFDA Breakthrough Device designation.
FinSMEs
15/03/2024